EYPT — EyePoint, Inc.

—
Nasdaq · Unknown · Unknown · CIK 1314102 ·
Last close
$0.30
Market Cap
$33.67M
52W High
$19.11
52W Low
$0.28
ADV30
13,775,381
Next earnings
2026-11-12
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 756,000 233,000 -96,877,000 -95,612,000 166,137,000 83,206,000 57,631,000
Jun 2026 507,000 507,000 -97,380,000 -94,470,000 228,191,000 110,458,000 61,780,000
Mar 2026 696,000 168,000 -87,226,000 -84,832,000 288,217,000 77,712,000 57,745,000
Dec 2025 620,000 245,000 -70,345,000 -67,609,000 363,996,000 101,821,000 57,883,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-267,298,000
Investing CF
$114,875,000
Financing CF
$191,738,000
CapEx
$-3,981,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.74
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,284,280,000
Inventory
$1,882,000
Receivables
$86,000
ST Investments
$70,014,000
EBIT TTM
$-305,192,000
Pretax Income TTM
$-306,507,000
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,579,000
EBITDA
$-349,039,008
Free Cash Flow
$-169,809,120
Enterprise Value
$-61,639,524
Total Cash
$118,213,000
Total Debt
$21,756,000
Shares Out
113,782,597
Trailing EPS
$-3.97
Book Value
$1.20
ROE
-221.9%
ROA
-105.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 31,371,000 -243,434,000 -231,962,000 363,996,000 57,883,000 306,113,000 -240,110,000
Dec 2024 43,273,000 -145,854,000 -130,870,000 418,465,000 81,964,000 336,501,000 -126,226,000
Dec 2023 46,018,000 -75,067,000 -70,795,000 355,184,000 88,861,000 266,323,000 1,875,000
Dec 2022 41,404,000 -78,938,000 -102,254,000 180,356,000 83,988,000 96,368,000 -65,005,000

TTM Snapshot

Revenues TTM
$2,788,000
NetIncome TTM
$-306,643,000
OpCashFlow TTM
—
Assets (Latest)
$228,191,000
Forward EPS
$-2.05

Max Pain — expiry 2026-12-18

max pain strike: $0.50 · spot: $0.27 · call oi: 8,754 · put oi: 9
Expected Move to 2026-12-18: ±$0.31 (112.13%) — implied range $-0.03 – $0.58 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
HYOR HyOrc Corp $33.66M $0.04 —
RPID RAPID MICRO BIOSYSTEMS, INC. $33.64M $0.74 —
PLLMF EDGE COPPER Corp $33.49M $0.20 —
LOMLF Lion One Metals Ltd. $33.96M $0.08 —
ACFN ACORN ENERGY, INC. $34.09M $13.45 —

News headlines (Yahoo Finance, 1h cache)

EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates
2026-11-12 12:35 · Yahoo
EyePoint: Q3 Earnings Snapshot
2026-11-12 12:32 · Yahoo
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
2026-11-12 12:00 · Yahoo
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
2026-11-06 12:00 · Yahoo
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-11-05 12:00 · Yahoo
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-28 13:00 · Yahoo
EyePoint (EYPT) Stock Sees Fair Value Cut After Duravyu Trial Setbacks
2026-10-21 02:15 · Yahoo
EyePoint halves workforce and ends Phase III trial early after endpoint miss
2026-10-20 11:37 · Yahoo
Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today?
2026-10-20 02:39 · Yahoo
EYPT Stock Layoffs: What to Know About the Latest EyePoint Job Cuts
2026-10-19 20:58 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.